Evgeny Kulesskiy
Helsinki, 00290, Finland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Functional temozolomide sensitivity testing of patient-specific glioblastoma stem cell cultures is predictive of clinical outcome.
Journal: Translational oncology
Published: May 30, 2022
Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments.
Journal: Briefings in bioinformatics
Published: June 11, 2021
Minimal information for Chemosensitivity assays (MICHA): A next-generation pipeline to enable the FAIRification of drug screening experiments.
Journal: bioRxiv : the preprint server for biology
Published: December 10, 2020
Identification and Tracking of Antiviral Drug Combinations.
Journal: Viruses
Published: September 22, 2020
High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro.
Journal: Biomolecules
Published: August 31, 2020
Chemical, Physical and Biological Triggers of Evolutionary Conserved Bcl-xL-Mediated Apoptosis.
Journal: Cancers
Published: June 11, 2020
Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment.
Journal: Clinical and translational medicine
Published: November 03, 2019
Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1.
Journal: The Journal of biological chemistry
Published: September 29, 2019
Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma.
Journal: BMC cancer
Published: December 03, 2018
Anagrelide for Gastrointestinal Stromal Tumor.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 12, 2018
Methods for High-throughput Drug Combination Screening and Synergy Scoring.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: January 19, 2018
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
Journal: Science translational medicine
Published: October 03, 2017
Last Updated: 09/26/2026